The inhibition of angiogenesis by antisense oligonucleotides to clusterin

被引：34

作者：

Jackson J.K. ^{[1
]}

Gleave M.E. ^{[2
]}

Gleave J. ^{[1
]}

Burt H.M. ^{[1
,3
]}

机构：

[1] Faculty of Pharmaceutical Sciences, Vancouver, BC

[2] Prostate Centre, Vancouver General Hospital, Vancouver, BC

[3] Faculty of Pharmaceutical Sciences, 2146 East Mall, UBC, Vancouver

来源：

Angiogenesis | 2005年 / 8卷 / 3期

关键词：

Angiogenesis; Antisense oligonucleotides; Apoptosis; Clusterin;

D O I：

10.1007/s10456-005-9018-5

中图分类号：

学科分类号：

摘要：

Angiogenesis is a primary disease target in ocular retinopathy and a secondary target in numerous other angiogenic diseases such as cancer, rheumatoid arthritis and psoriasis. Clinical trials using antiangiogenic antisense oligonucleotides (aso's) for the treatment of ocular disorders or cancer are well advanced. Clusterin aso's are currently under investigation for the treatment of prostate cancer. We have investigated the antiangiogenic properties of clusterin aso's using a capillary cell (HUVEC) viability assay. In this study we included aso's to known apoptosis modulators (bcl-2, bcl-xl and survivin) which were previously identified in HUVEC's. We have also studied the effect of clusterin aso's on angiogenesis using an in vitro, matrigel assay and on HUVEC apoptosis using an ELISA DNA fragmentation assay. Clusterin, bcl-2, bcl-xl and survivin aso's were all found to inhibit HUVEC growth. The apoptosis-inducing drugs paclitaxel, camptothecin and doxorubicin were also found to inhibit HUVEC proliferation. Combinations of aso's with these drugs demonstrated a minor additive but not synergistic inhibitory effect on HUVEC proliferation. Clusterin aso's were found to strongly inhibit angiogenesis and induce high levels of apoptosis in HUVECs. In cancer cells the prosurvival protein clusterin may protect the cells from apoptosis-inducing agents so that the clusterin aso's may act as chemosensitization agents. These data demonstrate a strong antiangiogenic action of clusterin aso's, that is not necessarily related to any chemosensitization effect of this agent. © Springer 2005.

引用

页码：229 / 238

页数：9

共 32 条

[1]

Stahel R.A., Zangemeister-Witte U., Antisense oligonucleotides for cancer therapy - An overview, Lung Cancer, 41, pp. 581-588, (2003)

[2]

El-Aneed A., Current strategies in cancer therapy, Eur J Pharmacol, 498, pp. 1-8, (2004)

[3]

Gleave M.E., Miyake H., Zellweger T., Et al., Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer, Urology, 58, 2 SUPPL. 1, pp. 39-49, (2001)

[4]

Zellweger T., Miyake H., July L.V., Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin, Neoplasia, 3, 4, pp. 360-367, (2001)

[5]

Miyake H., Hara I., Kamidono S., Et al., Synergistic chemsensitization and inhibition of tumor growth and metastasis by the antisense oligonucleotide targeting clusterin gene in a human bladder cancer model, Clin Cancer Res, 7, 12, pp. 4245-4252, (2001)

[6]

Zellweger T., Miyake H., July L.V., Et al., Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2′-O-(2-methoxy)ethyl chemistry, J Pharmacol Exp Ther, 298, 3, pp. 934-940, (2001)

[7]

Del Bufalo D., Trisciuciuoglio D., Scarsella M., Et al., Treatment of melanoma cells with a bcl-2/bcl-xL antisense oligonucleotide induces antiangiogenic activity, Oncogene, 22, pp. 8441-8447, (2003)

[8]

Henry S.P., Marcusson E.G., Vincent T.M., Dean N.M., Settings sights on the treatment of ocular angiogenesis using antisense oligonucleotides, Trends Pharmacol Sci, 25, 10, pp. 523-527, (2004)

[9]

Bhisitkul R.B., Robinson G.S., Moulton R.S., Et al., Arch Ophthalmol, 123, 2, pp. 214-219, (2005)

[10]

Marano R.J., Rakoczy P.E., Treatments for choroidal and retinal neovascularization: A focus on oligonucleotide therapy and delivery for the regulation of gene function, Clin Exp Ophthamol, 33, pp. 81-89, (2005)

← 1 2 3 4 →